MENOPUR® (HP-hMG) is a highly purified human menopausal
gonadotrophin containing a 1:1 ratio of follicle-stimulating hormone (FSH) and luteinising hormone (LH)-bioactivity.
MENOPUR® is indicated for treatment of female and male
infertility in the following groups of patients:
Anovulation, including polycystic ovarian disease (PCOD) in women who have been unresponsive to treatment with clomiphene citrate:
Women undergoing controlled ovarian hyperstimulation: MENOPUR® can induce the development of multiple follicles for assisted reproductive technologies (ART) (e.g. in vitro fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI))
Hypogonadotrophic hypogonadism in men: MENOPUR® may be given in combination with human chorionic gonadotrophin (e.g. CHORAGON®) for the stimulation of spermatogenesis. Patients with primary testicular failure are usually unresponsive
Job Code: UK-MR-2300028 - Date of preparation: July 2023
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.